Mathias Toft - Academia.edu (original) (raw)

Papers by Mathias Toft

Research paper thumbnail of Integrative analysis identifies bHLH transcription factors as contributors to Parkinson’s disease risk mechanisms

Scientific Reports, 2021

Genome-wide association studies (GWAS) have identified multiple genetic risk signals for Parkinso... more Genome-wide association studies (GWAS) have identified multiple genetic risk signals for Parkinson’s disease (PD), however translation into underlying biological mechanisms remains scarce. Genomic functional annotations of neurons provide new resources that may be integrated into analyses of GWAS findings. Altered transcription factor binding plays an important role in human diseases. Insight into transcriptional networks involved in PD risk mechanisms may thus improve our understanding of pathogenesis. We analysed overlap between genome-wide association signals in PD and open chromatin in neurons across multiple brain regions, finding a significant enrichment in the superior temporal cortex. The involvement of transcriptional networks was explored in neurons of the superior temporal cortex based on the location of candidate transcription factor motifs identified by two de novo motif discovery methods. Analyses were performed in parallel, both finding that PD risk variants significa...

Research paper thumbnail of Fine mapping of the HLA locus in Parkinson’s disease in Europeans

npj Parkinson's Disease

We fine mapped the leukocyte antigen (HLA) region in 13,770 Parkinson’s disease (PD) patients, 20... more We fine mapped the leukocyte antigen (HLA) region in 13,770 Parkinson’s disease (PD) patients, 20,214 proxy-cases, and 490,861 controls of European origin. Four HLA types were associated with PD after correction for multiple comparisons, HLA-DQA1*03:01, HLA-DQB1*03:02, HLA-DRB1*04:01, and HLA-DRB1*04:04. Haplotype analyses followed by amino acid analysis and conditional analyses suggested that the association is protective and primarily driven by three specific amino acid polymorphisms present in most HLA-DRB1*04 subtypes—11V, 13H, and 33H (OR = 0.87, 95% CI: 0.83–0.90, p

Research paper thumbnail of Allele-specific expression of Parkinson’s disease susceptibility genes in human brain

Scientific Reports

Genome-wide association studies have identified genetic variation in genomic loci associated with... more Genome-wide association studies have identified genetic variation in genomic loci associated with susceptibility to Parkinson’s disease (PD), the most common neurodegenerative movement disorder worldwide. We used allelic expression profiling of genes located within PD-associated loci to identify cis-regulatory variation affecting gene expression. DNA and RNA were extracted from post-mortem superior frontal gyrus tissue and whole blood samples from PD patients and controls. The relative allelic expression of transcribed SNPs in 12 GWAS risk genes was analysed by real-time qPCR. Allele-specific expression was identified for 9 out of 12 genes tested (GBA, TMEM175, RAB7L1, NUCKS1, MCCC1, BCKDK, ZNF646, LZTS3, and WDHD1) in brain tissue samples. Three genes (GPNMB, STK39 and SIPA1L2) did not show significant allele-specific effects. Allele-specific effects were confirmed in whole blood for three genes (BCKDK, LZTS3 and MCCC1), whereas two genes (RAB7L1 and NUCKS1) showed brain-specific a...

Research paper thumbnail of Missense mutations in DYT-TOR1A dystonia

Neurology Genetics

Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the ar... more Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article. The Article Processing Charge was funded by the authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Research paper thumbnail of Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms

Research paper thumbnail of Parkinson disease age of onset GWAS: defining heritability, genetic loci and a-synuclein mechanisms

Increasing evidence supports an extensive and complex genetic contribution to Parkinson's dis... more Increasing evidence supports an extensive and complex genetic contribution to Parkinson's disease (PD). Previous genome-wide association studies (GWAS) have shed light on the genetic basis of risk for this disease. However, the genetic determinants of PD age of onset are largely unknown. Here we performed an age of onset GWAS based on 28,568 PD cases. We estimated that the heritability of PD age of onset due to common genetic variation was ~0.11, lower than the overall heritability of risk for PD (~0.27) likely in part because of the subjective nature of this measure. We found two genome-wide significant association signals, one at SNCA and the other a protein-coding variant in TMEM175, both of which are known PD risk loci and a Bonferroni corrected significant effect at other known PD risk loci, INPP5F/BAG3, FAM47E/SCARB2, and MCCC1. In addition, we identified that GBA coding variant carriers had an earlier age of onset compared to non-carriers. Notably, SNCA, TMEM175, SCARB2, ...

Research paper thumbnail of TMEM230 variants in Parkinson’s disease

Research paper thumbnail of Expanding Parkinson's disease genetics: novel risk loci, genomic context, causal insights and heritable risk

We performed the largest genome-wide association study of PD to date, involving the analysis of 7... more We performed the largest genome-wide association study of PD to date, involving the analysis of 7.8M SNPs in 37.7K cases, 18.6K UK Biobank proxy-cases, and 1.4M controls. We identified 90 independent genome-wide significant signals across 78 loci, including 38 independent risk signals in 37 novel loci. These variants explained 26-36% of the heritable risk of PD. Tests of causality within a Mendelian randomization framework identified putatively causal genes for 70 risk signals. Tissue expression enrichment analysis suggested that signatures of PD loci were heavily brain-enriched, consistent with specific neuronal cell types being implicated from single cell expression data. We found significant genetic correlations with brain volumes, smoking status, and educational attainment. In sum, these data provide the most comprehensive understanding of the genetic architecture of PD to date by revealing many additional PD risk loci, providing a biological context for these risk factors, and ...

Research paper thumbnail of A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease

Research paper thumbnail of Multiple Microelectrode Recordings in STN-DBS Surgery for Parkinson's Disease: A Randomized Study

Movement disorders clinical practice

Subthalamic nucleus deep brain stimulation improves motor symptoms and fluctuations in advanced P... more Subthalamic nucleus deep brain stimulation improves motor symptoms and fluctuations in advanced Parkinson's disease, but the degree of clinical improvement depends on accurate anatomical electrode placement. Methods used to localize the sensory-motor part of the nucleus vary substantially. Using microelectrode recordings, at least three inserted microelectrodes are needed to obtain a three-dimensional map. Therefore, multiple simultaneously inserted microelectrodes should provide better guidance than single sequential microelectrodes. We aimed to compare the use of multiple simultaneous versus single sequential microelectrode recordings on efficacy and safety of subthalamic nucleus stimulation. Sixty patients were included in this double-blind, randomized study, 30 in each group. Primary outcome measures were the difference from baseline to 12 months in the MDS-UPDRS motor score (part III) in the off-medication state and quality of life using the Parkinson's Disease Question...

Research paper thumbnail of Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease

JAMA neurology, Jan 23, 2018

Pathogenic variants in LRRK2 are a relatively common genetic cause of Parkinson disease (PD). Cur... more Pathogenic variants in LRRK2 are a relatively common genetic cause of Parkinson disease (PD). Currently, the molecular mechanism underlying disease is unknown, and gain and loss of function (LOF) models of pathogenesis have been postulated. LRRK2 variants are reported to result in enhanced phosphorylation of substrates and increased cell death. However, the double knockout of Lrrk2 and its homologue Lrrk1 results in neurodegeneration in a mouse model, suggesting that disease may occur by LOF. Because LRRK2 inhibitors are currently in development as potential disease-modifying treatments in PD, it is critical to determine whether LOF variants in LRRK2 increase or decrease the risk of PD. To determine whether LRRK1 and LRRK2 LOF variants contribute to the risk of developing PD. To determine the prevailing mechanism of LRRK2-mediated disease in human populations, next-generation sequencing data from a large case-control cohort (>23 000 individuals) was analyzed for LOF variants in L...

Research paper thumbnail of Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease

Neurobiology of aging, Apr 1, 2018

SNCA missense mutations are a rare cause of autosomal dominant Parkinson's disease (PD). To d... more SNCA missense mutations are a rare cause of autosomal dominant Parkinson's disease (PD). To date, 6 missense mutations in SNCA have been nominated as causal. Here, we assess the frequency of these 6 mutations in public population databases and PD case-control data sets to determine their true pathogenicity. We found that 1 of the 6 reported SNCA mutations, His50Gln, was consistently identified in large population databases, and no enrichment was evident in PD cases compared to controls. These results suggest that His50Gln is probably not a pathogenic variant. This information is important to provide counseling for His50Gln carriers and has implications for the interpretation of His50Gln α-synuclein functional investigations.

Research paper thumbnail of Targeted high throughput sequencing in hereditary ataxia and spastic paraplegia

PLOS ONE, 2017

Hereditary ataxia and spastic paraplegia are heterogeneous monogenic neurodegenerative disorders.... more Hereditary ataxia and spastic paraplegia are heterogeneous monogenic neurodegenerative disorders. To date, a large number of individuals with such disorders remain undiagnosed. Here, we have assessed molecular diagnosis by gene panel sequencing in 105 early and late-onset hereditary ataxia and spastic paraplegia probands, in whom extensive previous investigations had failed to identify the genetic cause of disease. Pathogenic and likely-pathogenic variants were identified in 20 probands (19%) and variants of uncertain significance in ten probands (10%). Together these accounted for 30 probands (29%) and involved 18 different genes. Among several interesting findings, dominantly inherited KIF1A variants, p.(Val8Met) and p.(Ile27Thr) segregated in two independent families, both presenting with a pure spastic paraplegia phenotype. Two homozygous missense variants, p.(Gly4230Ser) and p.(Leu4221Val) were found in SACS in one consanguineous family, presenting with spastic ataxia and isolated cerebellar atrophy. The average disease duration in probands with pathogenic and likely-pathogenic variants was 31 years, ranging from 4 to 51 years. In conclusion, this study confirmed and expanded the clinical phenotypes associated with known disease genes. The results demonstrate that gene panel sequencing and similar sequencing approaches can serve as efficient diagnostic tools for different heterogeneous disorders. Early use of such strategies may help to reduce both costs and time of the diagnostic process.

Research paper thumbnail of A cumulative genetic risk score predicts progression in Parkinson's disease

Movement Disorders, 2016

The contribution of genetic variability to clinical heterogeneity in Parkinson's disease ... more The contribution of genetic variability to clinical heterogeneity in Parkinson's disease is insufficiently understood. We aimed to investigate the effect of cumulative genetic risk on clinical outcomes. In a single-center study of 336 patients we genotyped 19 independent susceptibility variants identified in genome-wide association studies of Parkinson's disease. We tested for association between a cumulative genetic risk score and 3 outcome measures: survival, time until progression to Hoehn and Yahr stage 3, and Unified Parkinson's Disease Rating Scale motor score severity. Genetic risk score was significantly associated with time from diagnosis to Hoehn and Yahr stage 3 in a Cox regression model (P = 0.010). We observed no clear association for the other outcomes. We present results linking cumulative genetic risk to a motor outcome in Parkinson's disease. Our findings provide a valuable starting point for future large-scale efforts to map the genetic determinants of phenotypic variability.

Research paper thumbnail of Rare variants in dementia genes and Parkinson's disease

European journal of human genetics : EJHG, Dec 22, 2016

Research paper thumbnail of A Scandinavian multi-centre study replicates 11 susceptibility loci from genome-wide association studies in Parkinson's disease

European Journal of Neurology, 2012

Research paper thumbnail of LRRK2 mutations are not common in Alzheimer's disease

Mechanisms of Ageing and Development, Nov 30, 2005

The development of common age-related neurodegenerative disorders as Parkinson&am... more The development of common age-related neurodegenerative disorders as Parkinson's disease and Alzheimer's disease (AD) are influenced by genetic factors. Recently, pathogenic mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified in familial Parkinsonism. Individuals in some of these families developed symptoms of dementia with Lewy-bodies and AD. The LRRK2 gene is also located within a locus on chromosome 12 reported in late-onset AD, and is therefore a good candidate gene for dementia. A series of 242 patients from Norway diagnosed clinically with dementia were included in the study, the majority were diagnosed with AD. Individuals were screened for the presence of seven known pathogenic mutations previously reported in the LRRK2 gene. We did not identify LRRK2 mutations in our series of dementia patients, indicating that known pathogenic mutations are not common in patients clinically diagnosed with AD. However, these results do not exclude a possible role of other genetic variants within the LRRK2 gene in AD or other forms of dementia.

Research paper thumbnail of Genetic studies of LRRK2 and PINK1 in Parkinson's disease

Page 1. Thesis for the degree of philosophiae doctor Trondheim, March 2007 Norwegian University o... more Page 1. Thesis for the degree of philosophiae doctor Trondheim, March 2007 Norwegian University of Science and Technology Faculty of Medicine Department of Neuroscience Mathias Toft Genetic studies of LRRK2 and PINK1 in Parkinson's disease Page 2. ...

Research paper thumbnail of Lrrk2 and Lewy body disease

Annals of Neurology, Feb 1, 2006

chronic stroke may have decreased the net inhibitory drive from the deafferented intact hand sens... more chronic stroke may have decreased the net inhibitory drive from the deafferented intact hand sensory representation over the homologous representation in the affected hemisphere, resulting in the documented improvement in GOA. This is consistent with work from animal experiments showing interhemispheric interactions between somatosensory cortices. 10,11 Regardless of the underlying mechanism, our findings underline the importance of somatosensory input originating in the intact hand on tactile function of the affected hand after stroke. The reported transient improvement of hand sensibility may be relevant to the design of interventional strategies in rehabilitation of somatosensory function after stroke.

Research paper thumbnail of Exome Variant Mining in Familial Parkinson Disease

Research paper thumbnail of Integrative analysis identifies bHLH transcription factors as contributors to Parkinson’s disease risk mechanisms

Scientific Reports, 2021

Genome-wide association studies (GWAS) have identified multiple genetic risk signals for Parkinso... more Genome-wide association studies (GWAS) have identified multiple genetic risk signals for Parkinson’s disease (PD), however translation into underlying biological mechanisms remains scarce. Genomic functional annotations of neurons provide new resources that may be integrated into analyses of GWAS findings. Altered transcription factor binding plays an important role in human diseases. Insight into transcriptional networks involved in PD risk mechanisms may thus improve our understanding of pathogenesis. We analysed overlap between genome-wide association signals in PD and open chromatin in neurons across multiple brain regions, finding a significant enrichment in the superior temporal cortex. The involvement of transcriptional networks was explored in neurons of the superior temporal cortex based on the location of candidate transcription factor motifs identified by two de novo motif discovery methods. Analyses were performed in parallel, both finding that PD risk variants significa...

Research paper thumbnail of Fine mapping of the HLA locus in Parkinson’s disease in Europeans

npj Parkinson's Disease

We fine mapped the leukocyte antigen (HLA) region in 13,770 Parkinson’s disease (PD) patients, 20... more We fine mapped the leukocyte antigen (HLA) region in 13,770 Parkinson’s disease (PD) patients, 20,214 proxy-cases, and 490,861 controls of European origin. Four HLA types were associated with PD after correction for multiple comparisons, HLA-DQA1*03:01, HLA-DQB1*03:02, HLA-DRB1*04:01, and HLA-DRB1*04:04. Haplotype analyses followed by amino acid analysis and conditional analyses suggested that the association is protective and primarily driven by three specific amino acid polymorphisms present in most HLA-DRB1*04 subtypes—11V, 13H, and 33H (OR = 0.87, 95% CI: 0.83–0.90, p

Research paper thumbnail of Allele-specific expression of Parkinson’s disease susceptibility genes in human brain

Scientific Reports

Genome-wide association studies have identified genetic variation in genomic loci associated with... more Genome-wide association studies have identified genetic variation in genomic loci associated with susceptibility to Parkinson’s disease (PD), the most common neurodegenerative movement disorder worldwide. We used allelic expression profiling of genes located within PD-associated loci to identify cis-regulatory variation affecting gene expression. DNA and RNA were extracted from post-mortem superior frontal gyrus tissue and whole blood samples from PD patients and controls. The relative allelic expression of transcribed SNPs in 12 GWAS risk genes was analysed by real-time qPCR. Allele-specific expression was identified for 9 out of 12 genes tested (GBA, TMEM175, RAB7L1, NUCKS1, MCCC1, BCKDK, ZNF646, LZTS3, and WDHD1) in brain tissue samples. Three genes (GPNMB, STK39 and SIPA1L2) did not show significant allele-specific effects. Allele-specific effects were confirmed in whole blood for three genes (BCKDK, LZTS3 and MCCC1), whereas two genes (RAB7L1 and NUCKS1) showed brain-specific a...

Research paper thumbnail of Missense mutations in DYT-TOR1A dystonia

Neurology Genetics

Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the ar... more Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article. The Article Processing Charge was funded by the authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Research paper thumbnail of Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms

Research paper thumbnail of Parkinson disease age of onset GWAS: defining heritability, genetic loci and a-synuclein mechanisms

Increasing evidence supports an extensive and complex genetic contribution to Parkinson's dis... more Increasing evidence supports an extensive and complex genetic contribution to Parkinson's disease (PD). Previous genome-wide association studies (GWAS) have shed light on the genetic basis of risk for this disease. However, the genetic determinants of PD age of onset are largely unknown. Here we performed an age of onset GWAS based on 28,568 PD cases. We estimated that the heritability of PD age of onset due to common genetic variation was ~0.11, lower than the overall heritability of risk for PD (~0.27) likely in part because of the subjective nature of this measure. We found two genome-wide significant association signals, one at SNCA and the other a protein-coding variant in TMEM175, both of which are known PD risk loci and a Bonferroni corrected significant effect at other known PD risk loci, INPP5F/BAG3, FAM47E/SCARB2, and MCCC1. In addition, we identified that GBA coding variant carriers had an earlier age of onset compared to non-carriers. Notably, SNCA, TMEM175, SCARB2, ...

Research paper thumbnail of TMEM230 variants in Parkinson’s disease

Research paper thumbnail of Expanding Parkinson's disease genetics: novel risk loci, genomic context, causal insights and heritable risk

We performed the largest genome-wide association study of PD to date, involving the analysis of 7... more We performed the largest genome-wide association study of PD to date, involving the analysis of 7.8M SNPs in 37.7K cases, 18.6K UK Biobank proxy-cases, and 1.4M controls. We identified 90 independent genome-wide significant signals across 78 loci, including 38 independent risk signals in 37 novel loci. These variants explained 26-36% of the heritable risk of PD. Tests of causality within a Mendelian randomization framework identified putatively causal genes for 70 risk signals. Tissue expression enrichment analysis suggested that signatures of PD loci were heavily brain-enriched, consistent with specific neuronal cell types being implicated from single cell expression data. We found significant genetic correlations with brain volumes, smoking status, and educational attainment. In sum, these data provide the most comprehensive understanding of the genetic architecture of PD to date by revealing many additional PD risk loci, providing a biological context for these risk factors, and ...

Research paper thumbnail of A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease

Research paper thumbnail of Multiple Microelectrode Recordings in STN-DBS Surgery for Parkinson's Disease: A Randomized Study

Movement disorders clinical practice

Subthalamic nucleus deep brain stimulation improves motor symptoms and fluctuations in advanced P... more Subthalamic nucleus deep brain stimulation improves motor symptoms and fluctuations in advanced Parkinson's disease, but the degree of clinical improvement depends on accurate anatomical electrode placement. Methods used to localize the sensory-motor part of the nucleus vary substantially. Using microelectrode recordings, at least three inserted microelectrodes are needed to obtain a three-dimensional map. Therefore, multiple simultaneously inserted microelectrodes should provide better guidance than single sequential microelectrodes. We aimed to compare the use of multiple simultaneous versus single sequential microelectrode recordings on efficacy and safety of subthalamic nucleus stimulation. Sixty patients were included in this double-blind, randomized study, 30 in each group. Primary outcome measures were the difference from baseline to 12 months in the MDS-UPDRS motor score (part III) in the off-medication state and quality of life using the Parkinson's Disease Question...

Research paper thumbnail of Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease

JAMA neurology, Jan 23, 2018

Pathogenic variants in LRRK2 are a relatively common genetic cause of Parkinson disease (PD). Cur... more Pathogenic variants in LRRK2 are a relatively common genetic cause of Parkinson disease (PD). Currently, the molecular mechanism underlying disease is unknown, and gain and loss of function (LOF) models of pathogenesis have been postulated. LRRK2 variants are reported to result in enhanced phosphorylation of substrates and increased cell death. However, the double knockout of Lrrk2 and its homologue Lrrk1 results in neurodegeneration in a mouse model, suggesting that disease may occur by LOF. Because LRRK2 inhibitors are currently in development as potential disease-modifying treatments in PD, it is critical to determine whether LOF variants in LRRK2 increase or decrease the risk of PD. To determine whether LRRK1 and LRRK2 LOF variants contribute to the risk of developing PD. To determine the prevailing mechanism of LRRK2-mediated disease in human populations, next-generation sequencing data from a large case-control cohort (>23 000 individuals) was analyzed for LOF variants in L...

Research paper thumbnail of Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease

Neurobiology of aging, Apr 1, 2018

SNCA missense mutations are a rare cause of autosomal dominant Parkinson's disease (PD). To d... more SNCA missense mutations are a rare cause of autosomal dominant Parkinson's disease (PD). To date, 6 missense mutations in SNCA have been nominated as causal. Here, we assess the frequency of these 6 mutations in public population databases and PD case-control data sets to determine their true pathogenicity. We found that 1 of the 6 reported SNCA mutations, His50Gln, was consistently identified in large population databases, and no enrichment was evident in PD cases compared to controls. These results suggest that His50Gln is probably not a pathogenic variant. This information is important to provide counseling for His50Gln carriers and has implications for the interpretation of His50Gln α-synuclein functional investigations.

Research paper thumbnail of Targeted high throughput sequencing in hereditary ataxia and spastic paraplegia

PLOS ONE, 2017

Hereditary ataxia and spastic paraplegia are heterogeneous monogenic neurodegenerative disorders.... more Hereditary ataxia and spastic paraplegia are heterogeneous monogenic neurodegenerative disorders. To date, a large number of individuals with such disorders remain undiagnosed. Here, we have assessed molecular diagnosis by gene panel sequencing in 105 early and late-onset hereditary ataxia and spastic paraplegia probands, in whom extensive previous investigations had failed to identify the genetic cause of disease. Pathogenic and likely-pathogenic variants were identified in 20 probands (19%) and variants of uncertain significance in ten probands (10%). Together these accounted for 30 probands (29%) and involved 18 different genes. Among several interesting findings, dominantly inherited KIF1A variants, p.(Val8Met) and p.(Ile27Thr) segregated in two independent families, both presenting with a pure spastic paraplegia phenotype. Two homozygous missense variants, p.(Gly4230Ser) and p.(Leu4221Val) were found in SACS in one consanguineous family, presenting with spastic ataxia and isolated cerebellar atrophy. The average disease duration in probands with pathogenic and likely-pathogenic variants was 31 years, ranging from 4 to 51 years. In conclusion, this study confirmed and expanded the clinical phenotypes associated with known disease genes. The results demonstrate that gene panel sequencing and similar sequencing approaches can serve as efficient diagnostic tools for different heterogeneous disorders. Early use of such strategies may help to reduce both costs and time of the diagnostic process.

Research paper thumbnail of A cumulative genetic risk score predicts progression in Parkinson's disease

Movement Disorders, 2016

The contribution of genetic variability to clinical heterogeneity in Parkinson's disease ... more The contribution of genetic variability to clinical heterogeneity in Parkinson's disease is insufficiently understood. We aimed to investigate the effect of cumulative genetic risk on clinical outcomes. In a single-center study of 336 patients we genotyped 19 independent susceptibility variants identified in genome-wide association studies of Parkinson's disease. We tested for association between a cumulative genetic risk score and 3 outcome measures: survival, time until progression to Hoehn and Yahr stage 3, and Unified Parkinson's Disease Rating Scale motor score severity. Genetic risk score was significantly associated with time from diagnosis to Hoehn and Yahr stage 3 in a Cox regression model (P = 0.010). We observed no clear association for the other outcomes. We present results linking cumulative genetic risk to a motor outcome in Parkinson's disease. Our findings provide a valuable starting point for future large-scale efforts to map the genetic determinants of phenotypic variability.

Research paper thumbnail of Rare variants in dementia genes and Parkinson's disease

European journal of human genetics : EJHG, Dec 22, 2016

Research paper thumbnail of A Scandinavian multi-centre study replicates 11 susceptibility loci from genome-wide association studies in Parkinson's disease

European Journal of Neurology, 2012

Research paper thumbnail of LRRK2 mutations are not common in Alzheimer's disease

Mechanisms of Ageing and Development, Nov 30, 2005

The development of common age-related neurodegenerative disorders as Parkinson&am... more The development of common age-related neurodegenerative disorders as Parkinson's disease and Alzheimer's disease (AD) are influenced by genetic factors. Recently, pathogenic mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified in familial Parkinsonism. Individuals in some of these families developed symptoms of dementia with Lewy-bodies and AD. The LRRK2 gene is also located within a locus on chromosome 12 reported in late-onset AD, and is therefore a good candidate gene for dementia. A series of 242 patients from Norway diagnosed clinically with dementia were included in the study, the majority were diagnosed with AD. Individuals were screened for the presence of seven known pathogenic mutations previously reported in the LRRK2 gene. We did not identify LRRK2 mutations in our series of dementia patients, indicating that known pathogenic mutations are not common in patients clinically diagnosed with AD. However, these results do not exclude a possible role of other genetic variants within the LRRK2 gene in AD or other forms of dementia.

Research paper thumbnail of Genetic studies of LRRK2 and PINK1 in Parkinson's disease

Page 1. Thesis for the degree of philosophiae doctor Trondheim, March 2007 Norwegian University o... more Page 1. Thesis for the degree of philosophiae doctor Trondheim, March 2007 Norwegian University of Science and Technology Faculty of Medicine Department of Neuroscience Mathias Toft Genetic studies of LRRK2 and PINK1 in Parkinson's disease Page 2. ...

Research paper thumbnail of Lrrk2 and Lewy body disease

Annals of Neurology, Feb 1, 2006

chronic stroke may have decreased the net inhibitory drive from the deafferented intact hand sens... more chronic stroke may have decreased the net inhibitory drive from the deafferented intact hand sensory representation over the homologous representation in the affected hemisphere, resulting in the documented improvement in GOA. This is consistent with work from animal experiments showing interhemispheric interactions between somatosensory cortices. 10,11 Regardless of the underlying mechanism, our findings underline the importance of somatosensory input originating in the intact hand on tactile function of the affected hand after stroke. The reported transient improvement of hand sensibility may be relevant to the design of interventional strategies in rehabilitation of somatosensory function after stroke.

Research paper thumbnail of Exome Variant Mining in Familial Parkinson Disease